Poziotinib
- Generic Name
- Poziotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21Cl2FN4O3
- CAS Number
- 1092364-38-9
- Unique Ingredient Identifier
- OEI6OOU6IK
- Background
Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among others.
- Indication
用于治疗非小细胞肺癌、乳腺癌和胃癌。对于吉非替尼和厄洛替尼耐药性EGFR L858R/T790M双突变细胞有很强的抑制作用。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT02544997
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath